
Clinical Trials - January 24, 2014
Zealand announce advancement in clinical study
Danish Zealand has announced that a milestone has been achieved in the advance of Lixilan towards start of phase III development in the 1st quarter of 2014. The milestone relates to the approval of the first phase III study protocol for Lixilan by a health authority, triggering a USD 15 million payment to Zealand. Lixisenatide […]

Collaboration - September 3, 2013
Zealand in R&D agreement with Lilly
The Danish pharma company Zealand Pharma announces peptide drug research and development collaboration agreement with Eli Lilly and Company. The two companies will together design and develop potentially novel therapeutic peptides for Type 2 diabetes and obesity. The development will be based on a novel approach discovered by Lilly and the two companies will share […]